echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > New COVID-19 vaccine candidate hAd5-COVID-19, which combines internal nuclear casing (N) and external prickly (S) proteins: the patient has been vaccinated.

    New COVID-19 vaccine candidate hAd5-COVID-19, which combines internal nuclear casing (N) and external prickly (S) proteins: the patient has been vaccinated.

    • Last Update: 2020-10-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Immunotherapy companies ImmunityBio and Nant Kwest announced today that the first patient has been vaccinated in a Phase I clinical trial of hAd5-COVID-19.
    hAd5-COVID-19 is a new COVID-19 vaccine candidate that combines the virus's internal nuclear shell (N) and external protrusion (S) proteins, and hAd5-COVID-19 has been engineered to activate T-cells and antibodies against SARS-CoV-2.
    is a novel COVID-19 vaccine that uses a second-generation adenovirus to deliver a variety of proteins such as SARS-CoV-2.
    Phase I trial, currently being conducted at Hoag Hospital in California, is currently recruiting healthy adults under the age of 55 to test the safety of the vaccine candidates.
    Patrick Soon-Shiong, Chairman and CEO of ImmunityBio and Nat Kwest, said, "Our candidate vaccine hdA5-COVID-19 has both a nuclear crust protein inside the virus particles and a prickly protein on the surface of the virus.
    We believe this dual mechanism is a key advantage that may stimulate T-cell-mediated and antibody-mediated immunity against SARS-CoV-2, which is an important difference from other candidates with only prickly proteins."
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.